Cargando…

A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia

Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Yin, Weiwei, Widjaya, Andy Samuel, Yang, Yueying, Liu, Yunhu, Jiang, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/
https://www.ncbi.nlm.nih.gov/pubmed/34849168
http://dx.doi.org/10.1016/j.ajps.2021.07.003
_version_ 1784602927731572736
author Liu, Xiao
Yin, Weiwei
Widjaya, Andy Samuel
Yang, Yueying
Liu, Yunhu
Jiang, Yanyan
author_facet Liu, Xiao
Yin, Weiwei
Widjaya, Andy Samuel
Yang, Yueying
Liu, Yunhu
Jiang, Yanyan
author_sort Liu, Xiao
collection PubMed
description Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid syndrome, serious drug resistance and the short half-life in vivo which lead to frequent and large dose administration limit the application of ATRA. In addition, the preparations of arsenic are conventional injections and tablets in clinic, which has poor patients' compliance caused by frequent long-term administration and serious side effects. In order to overcome the above limitations, a phospholipid phase separation gel (PPSG) loaded with ATO and ATRA was developed. ATO+ATRA-PPSG (AAP), as a biodegradable sustained-release delivery system, was the first achievement of co-delivery of hydrophilic ATO and lipophilic ATRA with high drug loading which is the main problem in the application of nano preparation. The prepared PPSG displayed high safety and biocompatibility. The drug in PPSG was released slowly and continuously in vivo and in vitro for up to 10 d, which could reduce the side effects caused by the fluctuation of blood drug concentration and solve the problem of the long treatment cycle and frequent administration. In vivo pharmacokinetics depicted that PPSG could improve the bioavailability, decrease the peak concentration, and prolong the t(1/2) of ATO and ATRA. Particularly, AAP significantly inhibited the tumor volume, extended the survival period of tumor-bearing mice, and promoted the differentiation of APL cells into normal cells. Therefore, ATO+ATRA-PPSG not only could co-load hydrophilic ATO and lipophilic ATRA according to the clinical dosage, but also possessed the sustained-release and long-acting treatment effect which was expected to reduce administration time and ameliorate compliance of patients. Thus, it had great potential for clinical transformation and application.
format Online
Article
Text
id pubmed-8609443
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shenyang Pharmaceutical University
record_format MEDLINE/PubMed
spelling pubmed-86094432021-11-29 A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia Liu, Xiao Yin, Weiwei Widjaya, Andy Samuel Yang, Yueying Liu, Yunhu Jiang, Yanyan Asian J Pharm Sci Original Research Paper Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid syndrome, serious drug resistance and the short half-life in vivo which lead to frequent and large dose administration limit the application of ATRA. In addition, the preparations of arsenic are conventional injections and tablets in clinic, which has poor patients' compliance caused by frequent long-term administration and serious side effects. In order to overcome the above limitations, a phospholipid phase separation gel (PPSG) loaded with ATO and ATRA was developed. ATO+ATRA-PPSG (AAP), as a biodegradable sustained-release delivery system, was the first achievement of co-delivery of hydrophilic ATO and lipophilic ATRA with high drug loading which is the main problem in the application of nano preparation. The prepared PPSG displayed high safety and biocompatibility. The drug in PPSG was released slowly and continuously in vivo and in vitro for up to 10 d, which could reduce the side effects caused by the fluctuation of blood drug concentration and solve the problem of the long treatment cycle and frequent administration. In vivo pharmacokinetics depicted that PPSG could improve the bioavailability, decrease the peak concentration, and prolong the t(1/2) of ATO and ATRA. Particularly, AAP significantly inhibited the tumor volume, extended the survival period of tumor-bearing mice, and promoted the differentiation of APL cells into normal cells. Therefore, ATO+ATRA-PPSG not only could co-load hydrophilic ATO and lipophilic ATRA according to the clinical dosage, but also possessed the sustained-release and long-acting treatment effect which was expected to reduce administration time and ameliorate compliance of patients. Thus, it had great potential for clinical transformation and application. Shenyang Pharmaceutical University 2021-09 2021-08-03 /pmc/articles/PMC8609443/ /pubmed/34849168 http://dx.doi.org/10.1016/j.ajps.2021.07.003 Text en © 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Paper
Liu, Xiao
Yin, Weiwei
Widjaya, Andy Samuel
Yang, Yueying
Liu, Yunhu
Jiang, Yanyan
A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title_full A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title_fullStr A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title_full_unstemmed A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title_short A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
title_sort practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/
https://www.ncbi.nlm.nih.gov/pubmed/34849168
http://dx.doi.org/10.1016/j.ajps.2021.07.003
work_keys_str_mv AT liuxiao apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT yinweiwei apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT widjayaandysamuel apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT yangyueying apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT liuyunhu apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT jiangyanyan apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT liuxiao practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT yinweiwei practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT widjayaandysamuel practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT yangyueying practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT liuyunhu practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia
AT jiangyanyan practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia